Research Article
Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?
Table 1
Patients’ characteristics at study enrolment.
| | Patients’ characteristics | Studied patients
(%) | Whole CF cohort
(%) | |
| | Gender (male/female) | 0.46 | 0.50 | 1 | | Median age (yrs [min.–max.]) | 25 18–43 | 30.1 18–62 | 0.12 | | Meconium ileus | 4 (16%) | 12 (21%) | 0.76 | | Pancreatic insufficiency | 22 (88%) | 49 (85.9%) | 1 | | Genotype | | | | | F508-F508 | 11 (44%) | 20 (35.1%) | 0.46 | | F508, other mutations | 12 (48%) | 31 (54%) | 0.63 | | 2 other mutations | 1 (4%) | 6 (10%) | 1 | | Medium BMI (kg/m2 [min.–max.]) | 19.3 17.0–29.4 | 21.4 17.0–32.9 | 0.11 | | Alcohol | 0 (0%) | 0 (0%) | 1 | | Diabetes mellitus | 4 (16%) | 13 (22.8%) | 0.57 | | Dyslipidemia | 1 (4%) | 1 (1.7%) | 0.52 | | Antibiotics | 17 (68%) | 41 (72%) | 0.79 | | Antifungal drugs | 19 (76%) | 29 (51%) | 0.051 | | UDCA treatment | 10 (40%) | 14 (24%) | 0.19 | | Creatinine clearance ≥ 70 mL/min | 25 (100%) | 57 (100%) | 1 |
| | FEV1 (%) | 67.6% 50.4–84.8 | 71.2% 47.5–94.9 | 0.33 |
|
|
BMI: body mass index; UDCA: ursodeoxycholic acid.
|
